Minimal Residual Disease Measured after Treatment with Bispecifics in Relapsed Multiple Myeloma: Experience from an Academic Medical Center

被引：0
|
作者：
Blanco, Alberto [1 ]
Chari, Ajai [2 ]
Martin, Thomas G. [2 ]
Arora, Shagun [2 ]
Chung, Alfred [2 ]
Kumar, Anupama Deepa [2 ]
Shah, Nina [2 ]
Wong, Sandy W. [2 ]
Takamatsu, Hiroyuki [3 ]
Martinez-Lopez, Joaquin [1 ]
Wolf, Jeffrey Lee [2 ]
机构：
[1] Hosp Univ 12 Octubre, Dept Hematol, Madrid, Spain
[2] Univ Calif San Francisco, Div Hematol Oncol, San Francisco, CA USA
[3] Kanazawa Univ, Dept Hematol, Kanazawa, Japan
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203768
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：7020 / 7021
页数：2
相关论文
共 50 条
  • [21] Minimal residual disease and imaging-guided consolidation strategies in newly diagnosed and relapsed refractory multiple myeloma
    Boeckle, David
    Tabares, Paula
    Zhou, Xiang
    Schimanski, Sven
    Steinhardt, Maximilian J.
    Bittrich, Max
    Seebacher, Elena
    Ulbrich, Maria
    Wilnit, Amy
    Metz, Corona
    Heidemeier, Anke
    Bley, Thorsten
    Werner, Rudolf
    Buck, Andreas
    Einsele, Hermann
    Kortuem, K. Martin
    Beilhack, Andreas
    Rasche, Leo
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (03) : 515 - 522
  • [22] Evaluation of Minimal Residual Disease (MRD) Negativity in Patients with Relapsed or Refractory Multiple Myeloma Treated in the Candor Study
    Landgren, Ola
    Weisel, Katja
    Dachs, Laura Rosinol
    Moreau, Philippe
    Turgut, Mehmet
    Hajek, Roman
    Mollee, Peter
    Kim, Jin Seok
    Zhang, Jianqi
    Go, Ning
    Morris, Christopher L.
    Usmani, Saad Z.
    BLOOD, 2020, 136
  • [23] VDCR as a treatment option for refractory or relapsed multiple myeloma in Bortezomib pretreated patients, a single center experience
    Dobrosch, L.
    Hahn-Ast, C.
    Mayer, K.
    von Lilienfeld-Toal, M.
    Brossart, P.
    Janzen, V
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 162 - 162
  • [24] Molecular monitoring of minimal residual disease after autologous or allogeneic transplantation for multiple myeloma.
    Corradini, P
    Tarella, C
    Astolfi, M
    Voena, C
    Ladetto, M
    Majolino, I
    Bacigalupo, A
    Boccadoro, M
    Pileri, A
    BLOOD, 1996, 88 (10) : 2464 - 2464
  • [25] Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma
    Bruno, B
    Ladetto, M
    Mordini, N
    Astolfi, M
    Rotta, M
    Cimolin, L
    Compagno, M
    Veneziano, L
    Aitoro, G
    Gallamini, A
    Storb, R
    Boccadoro, M
    BONE MARROW TRANSPLANTATION, 2003, 31 : S123 - S124
  • [26] The Prognostic Significance of Minimal Residual Disease Detection after Induction and ASCT to the Patients with Multiple Myeloma
    Yao, Weiqin
    Zhu Mingqing
    Yao Feirong
    Yan, Lingzhi
    Jin, Song
    Shang, Jingjing
    Yao, Ying
    Yan, Shuang
    Wu, Depei
    Fu, ChengCheng
    BLOOD, 2018, 132
  • [27] A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy
    Nath, Karthik
    Shekarkhand, Tala
    Salcedo, Meghan
    Derkach, Andriy
    Rueda, Siobhan
    Chansakul, Aisara
    Hulcrantz, Malin
    Korde, Neha
    Shah, Urvi A.
    Tan, Carlyn
    Chung, David J.
    Lahoud, Oscar B.
    Hassoun, Hani
    Lesokhin, Alexander M.
    Landau, Heather J.
    Shah, Gunjan
    Scordo, Michael
    Giralt, Sergio A.
    Usmani, Saad Z.
    Roshal, Mikhail
    Landgren, Ola
    Mailankody, Sham
    LEUKEMIA & LYMPHOMA, 2022, 63 (14) : 3488 - 3492
  • [28] Standardization of High Sensitivity Minimal Residual Disease Monitoring in Multiple Myeloma: An Experience in Tertiary Cancer Centre
    Subramanian, Papagudi
    Chatterjee, Gaurav
    Gokarn, Anant
    Gudapati, Prathyusha
    Deshpande, Nilesh
    Yajamanam, Badrinath
    Patkar, Nikhil
    Inamdar, Nitin
    Punatar, Sachin
    Bagal, Bhausaheb
    Jain, Hasmukh
    Sengar, Manju
    Khattry, Navin
    Gujral, Sumeet
    Tembhare, Prashant
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E183 - E183
  • [29] Real-world evidence on prognostic value of minimal residual disease in multiple myeloma: Czech experience
    Jelinek, Tomas
    Muronova, Ludmila
    Zihala, David
    Sevcikova, Tereza
    Popkova, Tereza
    Plonkova, Hana
    Venglar, Ondrej
    Pour, Ludek
    Stork, Martin
    Rihova, Lucie
    Bezdekova, Renata
    Minarik, Jiri
    Novak, Martin
    Jungova, Alexandra
    Chena, David
    Straub, Jan
    Spacek, Martin
    Rezacova, Vladimira
    Soucek, Ondrej
    Maisnar, Vladimir
    Radocha, Jakub
    Hajek, Roman
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S75 - S76
  • [30] Molecular quantitation of minimal residual disease in multiple myeloma patients achieving complete remission after treatment with Revlimid or Velcade.
    Thulien, KJ
    Blech, AR
    Reiman, T
    Pilarski, LM
    BLOOD, 2005, 106 (11) : 973A - 973A
12345